SSKN is a global leader in advanced laser and light-based devices for serious skin disorders.
The company's existing business is operationally cashflow positive, with cash from operations reaching $0.2M in 2024.
Recent expansions, such as new indications for inflammatory skin disorders and potential revenue opportunities in 2026, are poised to drive growth.
Strong Cashflow
$1.3M underlying cash from operations in 2024, adjusting for other income and interest payments.
TAM Expansion
Anticipated 3x increase in Total Addressable Market with CPT code expansion.
LaserOptek Lawsuit
Legal action against LaserOptek may bolster the company's cash position.
- The TAM increase and reimbursement per patient enhancements could significantly boost revenue potential.
- Legal actions like the LaserOptek lawsuit can impact competition dynamics and financial outcomes.
SSKN is positioned for growth with innovative products and strategic expansions in the dermatology field, supported by strong financial performance and potential market advantages.